Last reviewed · How we verify

rabeprazole and pantoprazole

PriCara, Unit of Ortho-McNeil, Inc. · FDA-approved active Small molecule Quality 5/100

rabeprazole and pantoprazole is a Small molecule drug developed by PriCara, Unit of Ortho-McNeil, Inc.. It is currently FDA-approved.

At a glance

Generic namerabeprazole and pantoprazole
SponsorPriCara, Unit of Ortho-McNeil, Inc.
ModalitySmall molecule
PhaseFDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about rabeprazole and pantoprazole

What is rabeprazole and pantoprazole?

rabeprazole and pantoprazole is a Small molecule drug developed by PriCara, Unit of Ortho-McNeil, Inc..

Who makes rabeprazole and pantoprazole?

rabeprazole and pantoprazole is developed and marketed by PriCara, Unit of Ortho-McNeil, Inc. (see full PriCara, Unit of Ortho-McNeil, Inc. pipeline at /company/pricara-unit-of-ortho-mcneil-inc).

What development phase is rabeprazole and pantoprazole in?

rabeprazole and pantoprazole is FDA-approved (marketed).

Related